SCHEDULE: Casdin Capital Boosts BioLife Solutions Stake to 15%

Casdin Capital, a key investor, has increased its beneficial ownership in BioLife Solutions, Inc. to 15.0% through a recent share acquisition.

Summary

• Casdin Capital, LLC, along with Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, and Eli Casdin (collectively, the "Reporting Persons"), reported beneficial ownership of 7,207,165 shares of BioLife Solutions, Inc. Common Stock.
• This ownership represents 15.0% of the Issuer's outstanding shares, based on 47,905,265 shares outstanding as of July 31, 2025.
• The Reporting Persons acquired an additional 500,000 shares of Common Stock on August 11, 2025, at a price of $22.60 per share.
• The funds for the share purchases originated from the working capital of the Fund, with no borrowed funds used for the direct purchase, other than for ordinary course working capital purposes.
• The Reporting Persons acquired the shares for investment purposes and reserve the right to engage with the Issuer's management and Board of Directors regarding alternatives to maximize shareholder value.

Sentiment

Score: 8

Explanation: The filing indicates a significant increase in a key investor's stake, coupled with a stated intent to maximize shareholder value, which is generally a positive signal for the company's strategic direction and potential future performance.

Positives

• A significant institutional investor, Casdin Capital, has increased its stake, signaling continued confidence in BioLife Solutions, Inc.
• The Reporting Persons explicitly state their intent to engage with management and the Board to explore alternatives to maximize shareholder value, which could lead to positive strategic initiatives.
• The acquisition of additional shares at $22.60 per share indicates a recent investment at a specific valuation point.

Risks

• The Reporting Persons reserve the right to effect changes in the Issuer's corporate structure, management, capitalization, or dividend policy, which could introduce uncertainty if such actions are pursued aggressively.
• While currently for investment, the Reporting Persons may dispose of shares or enter into other transactions, potentially impacting share price.

Future Outlook

The Reporting Persons have acquired shares for investment purposes and reserve the right to engage with BioLife Solutions' management and Board of Directors, other significant shareholders, and other persons to discuss alternatives to maximize shareholder value. They may also dispose of shares or enter into other transactions in the future.

Industry Context

BioLife Solutions operates in the life sciences tools and services sector, providing biopreservation and cell processing solutions critical for cell and gene therapy development. Casdin Capital's increased stake suggests continued investor interest and potential for strategic engagement within this high-growth biotechnology segment.

Legal Proceedings

• None of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) in the last five years.
• None of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws in the last five years.

Stakeholder Impact

• Shareholders: Potential for increased focus on shareholder value maximization due to active engagement from a significant investor.
• Management and Board: May face increased scrutiny and engagement from Casdin Capital regarding strategic direction and operational efficiency.

Next Steps

• Reporting Persons may continue to be in contact with BioLife Solutions' management, Board of Directors, and other significant shareholders.
• Reporting Persons reserve the right to act in concert with other shareholders or recommend courses of action to management and shareholders.
• Reporting Persons may dispose of or enter into other transactions in the shares they beneficially own.

Key Dates

Recommendation

The increased stake by a prominent life sciences investor like Casdin Capital, coupled with their stated intent to maximize shareholder value, suggests a belief in the company's underlying potential. This active engagement could lead to strategic initiatives that unlock value, making it an attractive opportunity for investors.

Keywords

BioLife Solutions, Casdin Capital, SEC Filing, Schedule 13D, Beneficial Ownership, Investment, Biotechnology, Life Sciences, Shareholder Value, Institutional Investor